In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Capitol Capsule: Regulatory, Legislative, Legal and Political Biopharma News

This article was originally published in Scrip

Executive Summary

This past week in US regulatory, legislative, legal and political news affecting the biopharmaceutical industry included the indictment of a former GlaxoSmithKline PLC senior-level manager, who went from being regarded as one of the world's top protein biochemists to a becoming a thief, scheming with one of her coworkers to steal trade secrets from the London-based drug and vaccine maker; the Senate Health panel chairman's decision to take a step-by-step approach for overhauling the US biomedical enterprise, which ignores several measures, like one focused on antibiotics development, that were included in the House 21st Century Cures Act; and threats by House and Senate lawmakers to bring criminal contempt actions against former Turing Pharmaceuticals Inc. CEO Martin Shkreli if he ignores subpoenas to testify and turn over documents about why his firm hiked up the price of a more than 60-year-old drug; plus other Washington news.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts